Semaphorin 7A inhibits platelet production from CD34+ progenitor cells

Journal of Thrombosis and Haemostasis

Volumn 10, Issue 6, 2012, Pages 1100-1108

  Jaimes, Y ^a   Gras, C ^a   Goudeva, L ^a   Buchholz, S ^a   Eiz Vesper, B ^a   Seltsam, A ^b   Immenschuh, S ^a   Blasczyk, R ^a   Figueiredo, C ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b Institute Springe   (Germany)

Author keywords

CD34+ progenitor cells; Megakaryocyte; Platelet; Platelet production; Semaphorin 7A

Indexed keywords

CD42A ANTIGEN; CD61 ANTIGEN; FIBRINOGEN RECEPTOR; FOCAL ADHESION KINASE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 6; INTERLEUKIN 8; LYMPHOCYTE ANTIGEN; SEMAPHORIN; SEMAPHORIN 7A; UNCLASSIFIED DRUG;

ARTICLE; CD34 SELECTION; CELL DENSITY; CELL DIFFERENTIATION; CELL STRUCTURE; CYTOKINE RELEASE; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; MEGAKARYOCYTE; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; STEM CELL; THROMBOCYTE; THROMBOCYTOPOIESIS; UPREGULATION;

ANTIBODIES; ANTIGENS, CD; ANTIGENS, CD29; ANTIGENS, CD34; ANTINEOPLASTIC AGENTS; BIOLOGICAL MARKERS; BLOOD PLATELETS; CELL DIFFERENTIATION; CELL SEPARATION; CELLS, CULTURED; CYTOKINES; ENZYME ACTIVATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; FOCAL ADHESION KINASE 1; GENE EXPRESSION REGULATION; GPI-LINKED PROTEINS; HUMANS; INFLAMMATION MEDIATORS; INTEGRIN BETA3; MEGAKARYOCYTE PROGENITOR CELLS; MEGAKARYOCYTES; PHOSPHORYLATION; PLATELET GLYCOPROTEIN GPIB-IX COMPLEX; PLATELET MEMBRANE GLYCOPROTEIN IIB; REAL-TIME POLYMERASE CHAIN REACTION; RNA, MESSENGER; SEMAPHORINS;

EID: 84861706634     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2012.04708.x     Document Type: Article

References (29)

1. Takegahara N, Kumanogoh A, Kikutani H. Semaphorins: a new class of immunoregulatory molecules. Philos Trans R Soc Lond B Biol Sci 2005; 360: 1673-80.
2. Pasterkamp RJ, Peschon JJ, Spriggs MK, Kolodkin AL. Semaphorin 7A promotes axon outgrowth through integrins and MAPKs. Nature 2003; 424: 398-405.
3. Love CA, Harlos K, Mavaddat N, Davis SJ, Stuart DI, Jones EY, Esnouf RM. The ligand-binding face of the semaphorins revealed by the high-resolution crystal structure of SEMA4D. Nat Struct Biol 2003; 10: 843-8.
4. Kruger RP, Aurandt J, Guan KL. Semaphorins command cells to move. Nat Rev Mol Cell Biol 2005; 6: 789-800.
5. Suzuki K, Okuno T, Yamamoto M, Pasterkamp RJ, Takegahara N, Takamatsu H, Kitao T, Takagi J, Rennert PD, Kolodkin AL, Kumanogoh A, Kikutani H. Semaphorin 7A initiates T-cell-mediated inflammatory responses through alpha1beta1 integrin. Nature 2007; 446: 680-4.
6. Figueiredo CZJ, Eiz-Vesper B, Blasczyk R, Seltsam A. Semaphorin 7A: a new modulator of NK cell function. Hum Immunol 2009; 70(Suppl. 1): S156.
7. Kang S, Okuno T, Takegahara N, Takamatsu H, Nojima S, Kimura T, Yoshida Y, Ito D, Ohmae S, You DJ, Toyofuku T, Jang MH, Kumanogoh A. Intestinal epithelial cell-derived semaphorin 7A negatively regulates development of colitis via alphavbeta1 integrin. J Immunol 2012; 188: 1108-16.
8. Cines DB, Liebman H, Stasi R. Pathobiology of secondary immune thrombocytopenia. Semin Hematol 2009; 46: S2-14.
9. Hassan HT, Zander AR. Thrombocytopenia after high-dose chemotherapy and autologous stem cell transplantation: an unresolved problem and possible approaches to resolve it. J Hematother 1996; 5: 407-14.
10. Rebulla P. Refractoriness to platelet transfusion. Curr Opin Hematol 2002; 9: 516-20.
11. Tijssen MR, van der Schoot CE, Voermans C, Zwaginga JJ. Clinical approaches involving thrombopoietin to shorten the period of thrombocytopenia after high-dose chemotherapy. Transfus Med Rev 2006; 20: 283-93.
12. Figueiredo C, Goudeva L, Horn PA, Eiz-Vesper B, Blasczyk R, Seltsam A. Generation of HLA-deficient platelets from hematopoietic progenitor cells. Transfusion 2010; 50: 1690-701.
13. Seltsam A, Strigens S, Levene C, Yahalom V, Moulds M, Moulds JJ, Hustinx H, Weisbach V, Figueroa D, Bade-Doeding C, DeLuca DS, Blasczyk R. The molecular diversity of Sema7A, the semaphorin that carries the JMH blood group antigens. Transfusion 2007; 47: 133-46.
14. Vadhan-Raj S. Management of chemotherapy-induced thrombocytopenia: current status of thrombopoietic agents. Semin Hematol 2009; 46: S26-32.
15. Fong KP, Barry C, Tran AN, Traxler EA, Wannemacher KM, Tang HY, Speicher KD, Blair IA, Speicher DW, Grosser T, Brass LF. Deciphering the human platelet sheddome. Blood 2011; 117: e15-26.
16. Matsunaga T, Tanaka I, Kobune M, Kawano Y, Tanaka M, Kuribayashi K, Iyama S, Sato T, Sato Y, Takimoto R, Takayama T, Kato J, Ninomiya T, Hamada H, Niitsu Y. Ex vivo large-scale generation of human platelets from cord blood CD34+ cells. Stem Cells 2006; 24: 2877-87.
17. Ma F, Ebihara Y, Umeda K, Sakai H, Hanada S, Zhang H, Zaike Y, Tsuchida E, Nakahata T, Nakauchi H, Tsuji K. Generation of functional erythrocytes from human embryonic stem cell-derived definitive hematopoiesis. Proc Natl Acad Sci U S A 2008; 105: 13087-92.
18. Kaushansky K. The molecular mechanisms that control thrombopoiesis. J Clin Invest 2005; 115: 3339-47.
19. Peeters K, Loyen S, van Kerckhoven S, Stoffels K, Hoylaerts MF, van Geet C, Freson K. Thrombopoietic effect of VPAC1 inhibition during megakaryopoiesis. Br J Haematol 2010; 151: 54-61.
20. Chang Y, Bluteau D, Debili N, Vainchenker W. From hematopoietic stem cells to platelets. J Thromb Haemost 2007; 5(Suppl. 1): 318-27.
21. Zimmet J, Ravid K. Polyploidy: occurrence in nature, mechanisms, and significance for the megakaryocyte-platelet system. Exp Hematol 2000; 28: 3-16.
22. Radley JM, Scurfield G. The mechanism of platelet release. Blood 1980; 56: 996-9.
23. Jiang S, Levine JD, Fu Y, Deng B, London R, Groopman JE, Avraham H. Cytokine production by primary bone marrow megakaryocytes. Blood 1994; 84: 4151-6.
24. Hamilton JA. GM-CSF in inflammation and autoimmunity. Trends Immunol 2002; 23: 403-8.
25. Waugh DJ, Wilson C. The interleukin-8 pathway in cancer. Clin Cancer Res 2008; 14: 6735-41.
26. Trikha M, Corringham R, Klein B, Rossi JF. Targeted anti-interleukin-6 monoclonal antibody therapy for cancer: a review of the rationale and clinical evidence. Clin Cancer Res 2003; 9: 4653-65.
27. Bernad A, Kopf M, Kulbacki R, Weich N, Koehler G, Gutierrez-Ramos JC. Interleukin-6 is required in vivo for the regulation of stem cells and committed progenitors of the hematopoietic system. Immunity 1994; 1: 725-31.
28. Emadi S, Clay D, Desterke C, Guerton B, Maquarre E, Charpentier A, Jasmin C, Le Bousse-Kerdiles MC. IL-8 and its CXCR1 and CXCR2 receptors participate in the control of megakaryocytic proliferation, differentiation, and ploidy in myeloid metaplasia with myelofibrosis. Blood 2005; 105: 464-73.
29. Nash RA, Gooley T, Davis C, Appelbaum FR. The Problem of Thrombocytopenia after Hematopoietic Stem Cell Transplantation. Oncologist 1996; 1: 371-80.